Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT05235516Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cadonilimab in Cervical Cancer (CC) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 54 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05235516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235516.